Navana Pharmaceuticals PLC (DSE:NAVANAPHAR)
Bangladesh · Delayed Price · Currency is BDT 70.50
-1.40 (-1.95%)
At close: Jun 16, 2026
Navana Pharmaceuticals Income Statement
Financials in millions BDT. Fiscal year is July - June.
Millions BDT. Fiscal year is Jul - Jun.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 |
| 10,567 | 8,843 | 6,898 | 5,706 | 4,759 | 3,607 | |
Revenue Growth (YoY) | 24.76% | 28.19% | 20.89% | 19.91% | 31.95% | 14.53% |
Cost of Revenue | 5,992 | 4,965 | 3,770 | 3,110 | 2,599 | 1,993 |
Gross Profit | 4,575 | 3,878 | 3,128 | 2,596 | 2,160 | 1,614 |
Selling, General & Admin | 3,083 | 2,432 | 2,136 | 1,841 | 1,591 | 1,265 |
Operating Expenses | 3,083 | 2,432 | 2,136 | 1,841 | 1,591 | 1,265 |
Operating Income | 1,492 | 1,446 | 991.84 | 755.72 | 569.6 | 348.59 |
Interest Expense | -611.33 | -726.63 | -463.57 | -234.89 | -200.42 | -75.18 |
Interest & Investment Income | 0.55 | 1.07 | 1.47 | 5.84 | 5.58 | 0.03 |
Currency Exchange Gain (Loss) | -68.16 | -54.08 | -25.18 | -33.38 | -93.98 | -2.52 |
Other Non Operating Income (Expenses) | 13.09 | 6.15 | 11.39 | -1.91 | 27.64 | 30.47 |
EBT Excluding Unusual Items | 826.58 | 672.48 | 515.95 | 491.38 | 308.42 | 301.39 |
Gain (Loss) on Sale of Investments | -14.8 | -10.46 | -0.88 | -42.3 | 82.9 | - |
Gain (Loss) on Sale of Assets | -1.22 | -0.09 | 1.18 | - | 0.47 | 1.02 |
Pretax Income | 810.56 | 661.93 | 516.25 | 449.08 | 391.79 | 302.41 |
Income Tax Expense | 204.43 | 174.12 | 111.62 | 92.14 | 117.78 | 100.12 |
Net Income | 606.13 | 487.81 | 404.63 | 356.94 | 274 | 202.29 |
Net Income to Common | 606.13 | 487.81 | 404.63 | 356.94 | 274 | 202.29 |
Net Income Growth | 35.30% | 20.56% | 13.36% | 30.27% | 35.45% | 47.23% |
Shares Outstanding (Basic) | 107 | 107 | 107 | 99 | 80 | 80 |
Shares Outstanding (Diluted) | 108 | 107 | 107 | 99 | 80 | 80 |
Shares Change (YoY) | 0.74% | - | 8.05% | 23.91% | - | - |
EPS (Basic) | 5.64 | 4.54 | 3.77 | 3.59 | 3.42 | 2.52 |
EPS (Diluted) | 5.60 | 4.54 | 3.77 | 3.59 | 3.42 | 2.52 |
EPS Growth | 34.41% | 20.56% | 4.92% | 5.13% | 35.45% | 47.23% |
Free Cash Flow | 1,894 | 1,444 | -625.1 | -1,404 | -1,160 | -399 |
Free Cash Flow Per Share | 17.50 | 13.44 | -5.82 | -14.13 | -14.45 | -4.97 |
Dividend Per Share | 1.400 | 1.400 | 1.400 | 1.300 | 1.100 | - |
Dividend Growth | - | - | 7.69% | 18.18% | - | - |
Gross Margin | 43.29% | 43.85% | 45.34% | 45.50% | 45.39% | 44.75% |
Operating Margin | 14.12% | 16.35% | 14.38% | 13.24% | 11.97% | 9.66% |
Profit Margin | 5.74% | 5.52% | 5.87% | 6.25% | 5.76% | 5.61% |
Free Cash Flow Margin | 17.92% | 16.33% | -9.06% | -24.61% | -24.37% | -11.06% |
EBITDA | 1,729 | 1,715 | 1,163 | 966.13 | 675.37 | 397.71 |
EBITDA Margin | 16.36% | 19.39% | 16.86% | 16.93% | 14.19% | 11.03% |
D&A For EBITDA | 236.65 | 268.77 | 171.25 | 210.41 | 105.77 | 49.12 |
EBIT | 1,492 | 1,446 | 991.84 | 755.72 | 569.6 | 348.59 |
EBIT Margin | 14.12% | 16.35% | 14.38% | 13.24% | 11.97% | 9.66% |
Effective Tax Rate | 25.22% | 26.30% | 21.62% | 20.52% | 30.06% | 33.11% |
Advertising Expenses | - | 42.15 | 38.4 | 33.13 | 80.86 | 19.55 |